Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management
remaining challenging. Amyloid positron emission tomography (PET) has become …

Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer's disease
(AD) using positron emission tomography (PET) has been approved for use in clinical …

Amyloid imaging using positron emission tomography (PET) has an emerging role in the
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …

Positron emission tomography (PET) of brain amyloid is a technology that has been
approved by Food and Drug Administration and European Medical Agency, but its clinical …

Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …

Positron emission tomography (PET) imaging of brain amyloid beta is now clinically
available in several countries including the United States and the United Kingdom, but not …

Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Importance Amyloid positron emission tomography (PET) allows the direct assessment of
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …

Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical
practice, but the extent of impact needs quantification. Objective: To provide an aggregated …